ERYTHROMYCIN IN THE TREATMENT OF DIPHTHERIA AND DIPHTHERIA CARRIER STATE

PEDIATRICS ◽  
1955 ◽  
Vol 16 (3) ◽  
pp. 335-344
Author(s):  
M. W. Beach ◽  
W. B. Gamble ◽  
C. H. Zemp ◽  
Margaret Q. Jenkins
Keyword(s):  
Clinical Trial ◽  
Respiratory Tract ◽  
Carrier State ◽  
Considerable Importance ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Nose And Throat ◽  
Active Disease ◽  
Primary Form

The treatment of acute diphtheria has not been drastically changed by the use of antibiotics. Antitoxin remains the primary form of therapy. However, the eradication of virulent diphtheria bacilli from the upper respiratory tract of patients with the active disease and of carriers is of considerable importance in the control of the disease. Streptomycin is effective in vitro and in infections produced experimentally but it has not been clinically evaluated in acute diphtheria or in the carrier state. Chlortetracycline, chloramphenicol, and oxytetracyline, although active against the causative organisms, have not had sufficient clinical trial to permit evaluation in the control of diphtheria and the carrier state. Penicillin eradicates C. diphtheriae from the nasopharynx in 75 per cent of patients within a period of 3 to 4 days. In this study erythromycin eradicated the C. diptheriae from the nose and throat in all of the cases in an average of 2 days in the active cases and in an average of 3 days in the carrier state. In the treatment of diphtheria erythromycin appears on the basis of the present and of previous studies to be the most promising antibiotic developed to date. Erythromycin is advocated as an adjunct to and not as a substitute for antitoxin in the treatment of acute diphtheria.

A Clinical Assessment of Locabiotal in the Treatment of Infections of the Nose and Throat

1977 ◽  
Vol 5 (2) ◽  
pp. 139-146
Author(s):  
M F Osman
Keyword(s):  
Clinical Trial ◽  
Particle Size ◽  
Side Effects ◽  
Respiratory Tract ◽  
Clinical Assessment ◽  
Patient Population ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Aerosol Inhaler ◽  
Nose And Throat

One hundred and twenty patients suffering from diseases of the nose and throat were admitted to an open clinical trial of the aerosol inhaler Locabiotal which contains the antibiotic fusafungine. The patient population was derived from three sources—out-patients, patients subjected to surgery and emergencies. The aerosol was administered five times daily to the throat or into the nose. The aerosol was highly effective in controlling infection and in relieving the various symptoms of the diseases treated. Variation in particle size was considered to be an advantage in penetrating various parts of the upper respiratory tract. Thirty-three patients experienced minor side-effects. These were thought to be due to misuse of the inhaler, or possible allergy to the antibiotic. This form of medication is recommended for a variety of diseases of the nose and throat.

scholarly journals STUDIES ON EXPERIMENTAL PNEUMONIA

1920 ◽  
Vol 32 (6) ◽  
pp. 719-744 ◽  
Author(s):  
Russell L. Cecil ◽  
Francis G. Blake
Keyword(s):  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Acute Inflammation ◽  
Early Stage ◽  
Acute Stage ◽  
Cebus Capucinus ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Lymphoid Structures ◽  
Nose And Throat

1. Virulent influenza bacilli, when injected into the nose and throat of monkeys (Cebus capucinus and Macacus syrichtus), excite an acute inflammation of the upper respiratory tract, characterized by swelling and hyperemia of the mucous membrane, infiltration of the mucosa and subrnucosa with leucocytes, desquamation of epithelial cells, and the production of a mucopurulent exudate. The accessory sinuses are often implicated in the infection. 2. Experimental Bacillus influenzæ infections of the upper respiratory tract are frequently accompanied or followed by bronchiolitis, peribronchial infiltration, and bronchopneumonia with hemorrhage and edema in the early stage, emphysema and bronchiectasis in the later stages. In general, the process closely resembles uncomplicated Bacillus influenzæ pneumonia in man. 3. The injection of virulent influenza bacilli directly into the trachea of monkeys induces in them an experimental bronchiolitis and hemorrhagic bronchopneumonia, similar in all respects to spontaneous Bacillus influenzæ pneumonia. 4. In experimental Bacillus influenzæinfections of either the upper or lower respiratory tract the influenza bacillus can usually be recovered during .the acute stage by culture, either pure or in association with other bacteria. 5. In experimental Bacillus influenzæ infections in monkeys characteristic changes occur in the thymus gland—hyperplasia of the follicles, distention of the lymphatic channels, and infiltration of the parenchyma with leucocytes. This enlargement appears to be merely part of a general hyperplasia of the lymphoid structures in the cervical and thoracic regions.

scholarly journals THE FREQUENCY OF BACILLUS INFLUENZÆ IN THE NOSE AND THROAT IN ACUTE LOBAR PNEUMONIA

1922 ◽  
Vol 35 (1) ◽  
pp. 7-15 ◽  
Author(s):  
Ernest G. Stillman
Keyword(s):  
Respiratory Tract ◽  
Upper Respiratory Tract ◽  
Lobar Pneumonia ◽  
Upper Respiratory ◽  
Nose And Throat

1. Bacillus influenza is frequently found in association with lobar pneumonia. 2. In lobar pneumonia both Bacillus influenza and pneumococcus are frequently found in the nose. 3. The influenza bacilli found in the upper respiratory tract of cases of lobar pneumonia are of various types. 4. The exact significance of these findings is at the present time not clear.

scholarly journals Kinetics of BoHV-1 Dissemination in an in Vitro Culture of Bovine Upper Respiratory Tract Mucosa Explants

ILAR Journal ◽  
2012 ◽  
Vol 53 (1) ◽  
pp. E43-E54 ◽  
Author(s):  
L. Steukers ◽  
A. P. Vandekerckhove ◽  
W. Van den Broeck ◽  
S. Glorieux ◽  
H. J. Nauwynck
Keyword(s):  
Respiratory Tract ◽  
In Vitro Culture ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Kinetics Of

scholarly journals Assessment of Postvaccine Immunity against Streptococcus pneumoniae in Patients with Asplenia, including an Analysis of Its Impact on Bacterial Flora of the Upper Respiratory Tract and Incidence of Infections

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Alina Olender ◽  
Katarzyna Małkińska ◽  
Jacek Roliński ◽  
Ewelina Grywalska ◽  
Elżbieta Pels ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Bacterial Flora ◽  
Carrier State ◽  
Control Group ◽  
Pathogenic Microorganisms ◽  
Upper Respiratory Tract ◽  
Specific Antibodies ◽  
Positive Effects ◽  
Upper Respiratory ◽  
Potentially Pathogenic Microorganisms

S. pneumoniae is a microorganism that may cause a serious threat in postsplenectomy patients due to a potentially invasive course of infection. In order to assess a protective activity after vaccination with the 23-valent vaccine, we made an analysis of the level of antibodies in patients with asplenia compared to a control group of healthy donors. Additionally, colonization by potentially pathogenic microorganisms of the upper respiratory tract was analyzed to determine the carrier state by strains with vaccine serotype. No such strains were found in the research, yet three non-vaccine-serotype strains were found. Colonization of the upper respiratory tract by potentially pathogenic microorganisms may be connected with increased susceptibility observed and incidence of infections in patients with asplenia. However, colonization by S. pneumoniae may not have an effect on the level of specific antibodies with the 23-valent vaccine against S. pneumoniae (PPV23) in postsplenectomy patients and healthy people. The response to vaccination against S. pneumoniae showed a lower level of specific antibodies in patients with splenectomy performed more than 2 years before the test than in patients with a recently removed spleen, i.e., from 1 month to 2 years before the test. Vaccination against pneumococci also has positive effects on incidence of other etiology infections, which is of high significance in the prophylaxis of infectious diseases in this group of patients.

scholarly journals Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses

2021 ◽  
Vol 8 ◽  
Author(s):  
Bianca Schulte ◽  
Benjamin Marx ◽  
Marek Korencak ◽  
Dorian Emmert ◽  
Souhaib Aldabbagh ◽  
...  
Keyword(s):  
Case Report ◽  
Respiratory Tract ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Upper Respiratory Tract ◽  
Protective Measures ◽  
Specific Antibodies ◽  
Household Members ◽  
Upper Respiratory

We present a case of SARS-CoV-2 B.1. 525 infection in a healthcare worker despite the presence of highly neutralizing, multivariant-specific antibodies 7 weeks after full vaccination with the mRNA vaccine BNT162b2. We show that the virus replicated to high levels in the upper respiratory tract over the course of several days in the presence of strong antibody responses. The virus was readily propagatable in vitro, demonstrating the potential to transmit to others, bolstered by the fact that several household members were equally infected. This highlights the importance of protective measures even in vaccinated individuals.

Sign in / Sign up

Export Citation Format

Share Document